SCI PHARMTECH, INC. 地富製藥科技股份有限公司

旭富製藥科技股份有限公司

董事會議記錄

MEETING MINUTES OF

RECTORS OF

SCI PHARMTECH, INC.

I. Time: 10:00 A.M., Dec. 2nd, 2011

II. Place: 19F, 145, Chien Kuo North Road, Section 2, Taipei, Taiwan

III. Chairman: Yon-Lian Wu

Secretary: Deiter Yang

IV. Attendees: Chintan Huang, Hung-Chih Wu, Ko-Lin Feng

Walt Cheng, Wei-Chyun Wong, Yon-Lian Wu

Also attendees: Deiter Yang (F&A Manager), Jacky Hsu (Internal Auditor)

- V. Report by the Chairperson: Dr. Wu directly commenced the meeting with required attendance.
- VI. Reporting Subjects:
 - 1. Review of minutes of last meeting and progress of implementation.

[Results] All attendees reviewed the minutes of last meeting and confirmed all the subjects had been fully implemented in accordance with the resolutions made.

2. Report on business and finance of importance.

[Results] Dr. Wu presented SCI's Jan.-Oct. operating results, which were in line with the figures budgeted.

3. Report on internal auditing

[Results] Internal auditor Jacky Hsu reported that SCI failed to report a newly used toxic chemical to the authorities due to a flaw in internal information conveyance and was fined NTD 60,000. Dr Wu added that the glitch happened the first time and

338 桃園縣蘆竹鄉海湖村16鄰186-2號 186-2, HAI-HU-TSUN, EU-CHU-HSIANG, TAOYUAN, TAIWAN 338 TEL: +886-3-3541700 FAX: +886-3-3543137

was corrected.



4. Report on IFRS transition progress.

[Results] The panel presented the material IFRS accounting principles to be adopted in 2013 financial statements.

VII. Approval Subjects:

1. 2011 business review and 2012 budget.

The subject was briefed by Dr. Wong and necessarily supplemented by Dr. Wu.

[Resolution] All directors approved 2012 budget unanimously, including the capital expenses for building and facilities for high-potent and sterile businesses.

2. 2012 internal auditing planning.

[Resolution] The plan was unanimously approved.

3. Amendment to Procedure Governing Asset Acquisition and Disposal.

The securities authorities required SCI setting up a loss cap for forward transactions in its Procedure to conform to the law.

[Resolution] The amendment was unanimously approved.

4. Amendment to internal control system.

The amendment is based on the corresponding amendment of the tax law.

[Resolution] The amendment was unanimously approved.

5. Management's compensation.

SCI PHARMTECH, INC. 地富製藥科技股份有限公司

338 桃園縣蘆竹鄉海湖村16鄰186-2號 186-2, HAI-HU-TSUN, LU-CHU-HSIANG, TAOYUAN, TAIWAN 338 TEL: +886-3-3541700 FAX: +886-3-3543137

According to the Securities and Exchange Act, the management's compensation should be recommended by Remuneration Committee and approved by the Board.

[Resolution] Remuneration Committee had earlier reviewed and recommended monthly salary and yearend bonus for members on the management. The Board unanimously approved the recommendation.

VIII. Miscellaneous:

Dr. Wu reported to board members the newly revised Declaration Letter of Directors, which is a request from the Taiwan Stock Exchange.

Yon-Lian Wu

Yon-Lian Wu, Chairman

Deiter Yang

Deiter Yang, Secretary